Down-regulation of bax-interacting factor-1 in colorectal adenocarcinoma

Domenico Coppola, Farah Khalil, Steven A. Eschrich, David Boulware, Timothy Yeatman, Hong-Gang Wang

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

BACKGROUND. Bax-interacting factor-1 (Bif-1) protein is a member of the endophilin B family that plays a critical role in apoptosis, autophagy, and mitochondrial morphology. Loss of Bif-1 suppresses programmed cell death and promotes tumorigenesis. The connection of Bif-1 to colorectal cancer remains to be evaluated. METHODS. To determine Bif-1 expression in human colorectal adenocarcinoma (CRC), the authors performed immunohistochemistry using stage-oriented cancer tissue microarrays containing 102 CRC samples of different stages and 38 samples of normal colorectal mucosa (NR). Formalin-fixed, paraffin-embedded core sections on the tissue array were immunostained using the avidin-biotin-peroxidase method and the anti-Bif-1 murine monoclonal antibody. Bif-1 staining was scored by 2 independent observers. To examine Bif-1 mRNA levels, the authors performed DNA microarray analysis of 205 CRC and 10 NR samples. RESULTS. Bif-1 expression was negative in 22.5% (23 of 102) of CRCs. Moderate to strong Bif-1 staining was identified in 36.3% (37 of 102) of the tumors, and weak staining was noted in 41.2% (42 of 102). Twenty-six of 38 (68.4%) NR samples exhibited moderate to strong Bif-1 immunoreactivity, and none of them was negative. In 12 (31.6%) cases NR demonstrated weak Bif-1 stain. The mean (median) scores for CRCs and NR differed significantly: 3.2 (3.0) and 5.2 (6.0), respectively (P =.0003). The percentage of cases with negative expression also differed significantly between NR and CRC (P =.002). Decreased Bif-1 expression in CRCs was confirmed at the mRNA level by microarray analysis. CONCLUSIONS. The authors report the down-regulation of Bif-1 during the transition from NR to CRC, a novel finding in agreement with the tumor suppressor function of Bif-1.

Original languageEnglish (US)
Pages (from-to)2665-2670
Number of pages6
JournalCancer
Volume113
Issue number10
DOIs
StatePublished - Nov 15 2008

Fingerprint

Adenocarcinoma
Down-Regulation
Microarray Analysis
Staining and Labeling
Neoplasms
Messenger RNA
Avidin
Autophagy
Biotin
Oligonucleotide Array Sequence Analysis
Paraffin
Formaldehyde
Peroxidase
Colorectal Neoplasms
Carcinogenesis
Mucous Membrane
Cell Death
Coloring Agents
Immunohistochemistry
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Coppola, D., Khalil, F., Eschrich, S. A., Boulware, D., Yeatman, T., & Wang, H-G. (2008). Down-regulation of bax-interacting factor-1 in colorectal adenocarcinoma. Cancer, 113(10), 2665-2670. https://doi.org/10.1002/cncr.23892
Coppola, Domenico ; Khalil, Farah ; Eschrich, Steven A. ; Boulware, David ; Yeatman, Timothy ; Wang, Hong-Gang. / Down-regulation of bax-interacting factor-1 in colorectal adenocarcinoma. In: Cancer. 2008 ; Vol. 113, No. 10. pp. 2665-2670.
@article{a98ca98f9ade42efb95d137831d873a2,
title = "Down-regulation of bax-interacting factor-1 in colorectal adenocarcinoma",
abstract = "BACKGROUND. Bax-interacting factor-1 (Bif-1) protein is a member of the endophilin B family that plays a critical role in apoptosis, autophagy, and mitochondrial morphology. Loss of Bif-1 suppresses programmed cell death and promotes tumorigenesis. The connection of Bif-1 to colorectal cancer remains to be evaluated. METHODS. To determine Bif-1 expression in human colorectal adenocarcinoma (CRC), the authors performed immunohistochemistry using stage-oriented cancer tissue microarrays containing 102 CRC samples of different stages and 38 samples of normal colorectal mucosa (NR). Formalin-fixed, paraffin-embedded core sections on the tissue array were immunostained using the avidin-biotin-peroxidase method and the anti-Bif-1 murine monoclonal antibody. Bif-1 staining was scored by 2 independent observers. To examine Bif-1 mRNA levels, the authors performed DNA microarray analysis of 205 CRC and 10 NR samples. RESULTS. Bif-1 expression was negative in 22.5{\%} (23 of 102) of CRCs. Moderate to strong Bif-1 staining was identified in 36.3{\%} (37 of 102) of the tumors, and weak staining was noted in 41.2{\%} (42 of 102). Twenty-six of 38 (68.4{\%}) NR samples exhibited moderate to strong Bif-1 immunoreactivity, and none of them was negative. In 12 (31.6{\%}) cases NR demonstrated weak Bif-1 stain. The mean (median) scores for CRCs and NR differed significantly: 3.2 (3.0) and 5.2 (6.0), respectively (P =.0003). The percentage of cases with negative expression also differed significantly between NR and CRC (P =.002). Decreased Bif-1 expression in CRCs was confirmed at the mRNA level by microarray analysis. CONCLUSIONS. The authors report the down-regulation of Bif-1 during the transition from NR to CRC, a novel finding in agreement with the tumor suppressor function of Bif-1.",
author = "Domenico Coppola and Farah Khalil and Eschrich, {Steven A.} and David Boulware and Timothy Yeatman and Hong-Gang Wang",
year = "2008",
month = "11",
day = "15",
doi = "10.1002/cncr.23892",
language = "English (US)",
volume = "113",
pages = "2665--2670",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

Coppola, D, Khalil, F, Eschrich, SA, Boulware, D, Yeatman, T & Wang, H-G 2008, 'Down-regulation of bax-interacting factor-1 in colorectal adenocarcinoma', Cancer, vol. 113, no. 10, pp. 2665-2670. https://doi.org/10.1002/cncr.23892

Down-regulation of bax-interacting factor-1 in colorectal adenocarcinoma. / Coppola, Domenico; Khalil, Farah; Eschrich, Steven A.; Boulware, David; Yeatman, Timothy; Wang, Hong-Gang.

In: Cancer, Vol. 113, No. 10, 15.11.2008, p. 2665-2670.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Down-regulation of bax-interacting factor-1 in colorectal adenocarcinoma

AU - Coppola, Domenico

AU - Khalil, Farah

AU - Eschrich, Steven A.

AU - Boulware, David

AU - Yeatman, Timothy

AU - Wang, Hong-Gang

PY - 2008/11/15

Y1 - 2008/11/15

N2 - BACKGROUND. Bax-interacting factor-1 (Bif-1) protein is a member of the endophilin B family that plays a critical role in apoptosis, autophagy, and mitochondrial morphology. Loss of Bif-1 suppresses programmed cell death and promotes tumorigenesis. The connection of Bif-1 to colorectal cancer remains to be evaluated. METHODS. To determine Bif-1 expression in human colorectal adenocarcinoma (CRC), the authors performed immunohistochemistry using stage-oriented cancer tissue microarrays containing 102 CRC samples of different stages and 38 samples of normal colorectal mucosa (NR). Formalin-fixed, paraffin-embedded core sections on the tissue array were immunostained using the avidin-biotin-peroxidase method and the anti-Bif-1 murine monoclonal antibody. Bif-1 staining was scored by 2 independent observers. To examine Bif-1 mRNA levels, the authors performed DNA microarray analysis of 205 CRC and 10 NR samples. RESULTS. Bif-1 expression was negative in 22.5% (23 of 102) of CRCs. Moderate to strong Bif-1 staining was identified in 36.3% (37 of 102) of the tumors, and weak staining was noted in 41.2% (42 of 102). Twenty-six of 38 (68.4%) NR samples exhibited moderate to strong Bif-1 immunoreactivity, and none of them was negative. In 12 (31.6%) cases NR demonstrated weak Bif-1 stain. The mean (median) scores for CRCs and NR differed significantly: 3.2 (3.0) and 5.2 (6.0), respectively (P =.0003). The percentage of cases with negative expression also differed significantly between NR and CRC (P =.002). Decreased Bif-1 expression in CRCs was confirmed at the mRNA level by microarray analysis. CONCLUSIONS. The authors report the down-regulation of Bif-1 during the transition from NR to CRC, a novel finding in agreement with the tumor suppressor function of Bif-1.

AB - BACKGROUND. Bax-interacting factor-1 (Bif-1) protein is a member of the endophilin B family that plays a critical role in apoptosis, autophagy, and mitochondrial morphology. Loss of Bif-1 suppresses programmed cell death and promotes tumorigenesis. The connection of Bif-1 to colorectal cancer remains to be evaluated. METHODS. To determine Bif-1 expression in human colorectal adenocarcinoma (CRC), the authors performed immunohistochemistry using stage-oriented cancer tissue microarrays containing 102 CRC samples of different stages and 38 samples of normal colorectal mucosa (NR). Formalin-fixed, paraffin-embedded core sections on the tissue array were immunostained using the avidin-biotin-peroxidase method and the anti-Bif-1 murine monoclonal antibody. Bif-1 staining was scored by 2 independent observers. To examine Bif-1 mRNA levels, the authors performed DNA microarray analysis of 205 CRC and 10 NR samples. RESULTS. Bif-1 expression was negative in 22.5% (23 of 102) of CRCs. Moderate to strong Bif-1 staining was identified in 36.3% (37 of 102) of the tumors, and weak staining was noted in 41.2% (42 of 102). Twenty-six of 38 (68.4%) NR samples exhibited moderate to strong Bif-1 immunoreactivity, and none of them was negative. In 12 (31.6%) cases NR demonstrated weak Bif-1 stain. The mean (median) scores for CRCs and NR differed significantly: 3.2 (3.0) and 5.2 (6.0), respectively (P =.0003). The percentage of cases with negative expression also differed significantly between NR and CRC (P =.002). Decreased Bif-1 expression in CRCs was confirmed at the mRNA level by microarray analysis. CONCLUSIONS. The authors report the down-regulation of Bif-1 during the transition from NR to CRC, a novel finding in agreement with the tumor suppressor function of Bif-1.

UR - http://www.scopus.com/inward/record.url?scp=55849126198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55849126198&partnerID=8YFLogxK

U2 - 10.1002/cncr.23892

DO - 10.1002/cncr.23892

M3 - Article

C2 - 18833585

AN - SCOPUS:55849126198

VL - 113

SP - 2665

EP - 2670

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -

Coppola D, Khalil F, Eschrich SA, Boulware D, Yeatman T, Wang H-G. Down-regulation of bax-interacting factor-1 in colorectal adenocarcinoma. Cancer. 2008 Nov 15;113(10):2665-2670. https://doi.org/10.1002/cncr.23892